Prescriptions for alternative versions of Mylan's EpiPen device have almost quadrupled in 2017, according to a new report from athenaInsight.
To compile the report, athenaResearch analyzed more than 60,000 prescriptions for epinephrine auto-injectors written for 50,000 patients across the country since the start of 2016.
In December 2016, 5.3 percent of prescriptions represented alternative epinephrine auto-injector devices. This February, that figure spiked to 28.9 percent of total prescriptions.
New generic EpiPen options entering the market, along with changes from insurers, may be responsible for the sudden jump, the report suggests.
More articles on supply chain:
10 drugmakers with highest direct-to-consumer ad spending in 2016
The 'price hikes fuel innovation' argument is invalid, researchers say
Trump's Supreme Court nominee advocates legal protection for devicemakers